1-9 of 9
John M. Lambert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4531: Effects of drug load on therapeutic index for antibody-maytansinoid conjugates

Free
Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder, Jennifer Coccia, Leanne Lanieri, Rassol Laleau, Qifeng Qiu, Rui Wu, Erica Hong, Megan Bogalhas, Lintao Wang, Erin K. Maloney, Olga Ab, Hans K. Erickson, Thomas A. Keating, Ravi Chari, John M. Lambert
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4531.
https://doi.org/10.1158/1538-7445.AM2015-4531
Published: 01 August 2015
View articletitled, Abstract 4531: Effects of drug load on therapeutic index for antibody-maytansinoid conjugates
Journal Articles

Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors

Free
Yulius Y. Setiady, Ling Dong, Anna Skaletskaya, Jan Pinkas, Robert J. Lutz, John M. Lambert, Thomas Chittenden
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4513.
https://doi.org/10.1158/1538-7445.AM2014-4513
Published: 01 October 2014
View articletitled, Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors
Journal Articles

Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.

Free
Yulius Y. Setiady, Peter U. Park, Jose F. Ponte, Ling Dong, Anna Skaletskaya, Jennifer A. Coccia, Erica Hong, Lauren Clancy, Lingyun Rui, Jan Pinkas, Robert J. Lutz, John M. Lambert, Thomas D. Chittenden
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5463.
https://doi.org/10.1158/1538-7445.AM2013-5463
Published: 15 April 2013
View articletitled, Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Journal Articles

Abstract 5467: IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.

Free
Thomas D. Chittenden, Yulius Y. Setiady, Peter U. Park, Jose F. Ponte, Ling Dong, Anna Skaletskaya, Christina N. Carrigan, Alfred A. Villaluz, Jan Pinkas, Robert J. Lutz, John M. Lambert
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5467.
https://doi.org/10.1158/1538-7445.AM2013-5467
Published: 15 April 2013
View articletitled, Abstract 5467: IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.
Journal Articles

Abstract 4565: IMGN529: A therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia

Free
Jutta Deckert, Michele F. Mayo, Yong Yi, Min Li, Sharon Chicklas, Daniel J. Tavares, Jan Pinkas, Thomas D. Chittenden, Robert J. Lutz, John M. Lambert, Peter U. Park
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4565.
https://doi.org/10.1158/1538-7445.AM2011-4565
Published: 15 April 2011
View articletitled, Abstract 4565: IMGN529: A therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia
Journal Articles

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Free
Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, Lisa M. Crocker, Kathryn L. Parsons, Elaine Mai, Walter A. Blättler, John M. Lambert, Ravi V.J. Chari, Robert J. Lutz, Wai Lee T. Wong, Frederic S. Jacobson, Hartmut Koeppen, Ralph H. Schwall, Sara R. Kenkare-Mitra, Susan D. Spencer, Mark X. Sliwkowski
Journal: Cancer Research
Cancer Res (2008) 68 (22): 9280–9290.
https://doi.org/10.1158/0008-5472.CAN-08-1776
Published: 14 November 2008
View articletitled, Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Open the PDF for Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate in another window
Journal Articles

HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice

Free
Robert J. Lutz, Hongsheng Xie, Wayne C. Widdison, Peter S. Wunderli, Rita M. Steeves, Victor S. Goldmacher, John M. Lambert, Ravi V. J. Chari
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 334–335.
Published: 01 May 2005
View articletitled, HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice
Journal Articles

Correlation between in Vivo Toxicity and Preclinical in Vitro Parameters for the Immunotoxin Anti-B4-blocked Ricin

Free
Michael L. Grossbard, John M. Lambert, Victor S. Goldmacher, Walter A. Blättler, Lee M. Nadler
Journal: Cancer Research
Cancer Res (1992) 52 (15): 4200–4207.
Published: 01 August 1992
View articletitled, Correlation between in Vivo Toxicity and Preclinical in Vitro Parameters for the Immunotoxin Anti-B4-blocked Ricin
Open the PDF for Correlation between in Vivo Toxicity and Preclinical in Vitro Parameters for the Immunotoxin Anti-B4-blocked Ricin in another window
Journal Articles

An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use

Free
John M. Lambert, Victor S. Goldmacher, Albert R. Collinson, Lee M. Nadler, Walter A. Blättler
Journal: Cancer Research
Cancer Res (1991) 51 (23_Part_1): 6236–6242.
Published: 12 January 1991
View articletitled, An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use
Open the PDF for An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use in another window